SOPHiA GENETICS SA (SOPH): who owns it and who trades it
As of Nov 16, 2026, SOPH insiders reported 146 open-market sales worth $5.2M and 3 purchases worth $377K in the last 12 months, with 99% of the sale value made under pre-set 10b5-1 plans. The largest seller was Jurgi Camblong (CEO), with $2.8M. 6 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Sophia Genetics Sa
From the latest filingsOverall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns SOPH
72 funds and institutions reported SOPH shares worth $213M at the end of Q2 2026, about 54% of the company. The largest holder is Generation Investment Management LLP with 9.9%.
Funds and institutions (13F) 54%Everyone else 46%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Generation Investment Management LLP | 6.79M | 9.91% | $39.2M | No change |
| AIGH Capital Management LLC | 3.95M | 5.77% | $22.8M | New |
| Akre Capital Management LLC | 3.72M | 5.43% | $21.5M | No change |
| Royce & Associates LP | 3.38M | 4.94% | $19.5M | +86% |
| Principal Financial Group Inc | 2.36M | 3.45% | $13.6M | +68% |
| Ameriprise Financial Inc | 2.22M | 3.24% | $12.8M | New |
| Banque Pictet & Cie SA | 2.21M | 3.22% | $12.7M | No change |
| AWM Investment Company, Inc. | 1.70M | 2.48% | $9.8M | New |
| Soleus Capital Management, L.P. | 1.56M | 2.29% | $9M | -15% |
| Silvercrest Asset Management Group LLC | 1.43M | 2.09% | $8.2M | New |
| Alta Wealth Advisors LLC | 1.41M | 2.06% | $8.1M | No change |
| Kennedy Capital Management LLC | 917,977 | 1.34% | $5.3M | -1% |
| Archon Capital Management LLC | 691,413 | 1.01% | $4M | +57% |
| Essex Investment Management Co LLC | 663,428 | 0.97% | $3.8M | -4% |
| Ensign Peak Advisors, Inc | 444,654 | 0.65% | $2.6M | -0% |
| Hodges Capital Management Inc. | 409,073 | 0.60% | $2.4M | -6% |
| Bank Pictet & Cie (Europe) AG | 255,200 | 0.37% | $1.5M | No change |
| Legato Capital Management LLC | 223,230 | 0.33% | $1.3M | +3% |
| 1492 Capital Management LLC | 222,194 | 0.32% | $1.3M | -2% |
| Edmond DE Rothschild Holding S.a. | 200,004 | 0.29% | $1.2M | -2% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, SOPH insiders reported $377K of open-market purchases and $5.2M of sales. 99% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $7.96 | $31.8K | Form 4 |
| Nov 12, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $7.68 | $38.4K | Form 4 |
| Nov 10, 2026 | Jurgi Camblong | Chair | Sale plan | 8,500 | $7.76 | $65.9K | Form 4 |
| Nov 10, 2026 | Kathy L Hibbs | Director | Sale plan | 6,250 | $7.76 | $48.5K | Form 4 |
| Nov 9, 2026 | Well Daan Van | Chief Legal Officer | Sale plan | 1,411 | $7.44 | $10.5K | Form 4 |
| Nov 6, 2026 | George Cardoza | CFO | Purchase | 20,000 | $7.06 | $141K | Form 4 |
| Nov 6, 2026 | Ross Muken | CEO | Purchase | 20,000 | $6.86 | $137K | Form 4 |
| Oct 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $7.18 | $28.7K | Form 4 |
| Oct 12, 2026 | Jurgi Camblong | Chair | Sale plan | 8,500 | $7.26 | $61.7K | Form 4 |
| Oct 12, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $7.26 | $36.3K | Form 4 |
| Oct 5, 2026 | George Cardoza | CFO | Sale plan | 1,592 | $8.10 | $12.9K | Form 4 |
| Oct 5, 2026 | Jurgi Camblong | Chair | Sale plan | 40,172 | $8.13 | $327K | Form 4 |
| Oct 5, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 7,394 | $8.13 | $60.1K | Form 4 |
| Oct 5, 2026 | Ross Muken | CEO | Sale plan | 9,838 | $8.13 | $80K | Form 4 |
| Oct 5, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 185 | $8.06 | $1.5K | Form 4 |
| Oct 5, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 31 | $7.92 | $246 | Form 4 |
| Oct 5, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 7,394 | $8.12 | $60.1K | Form 4 |
| Oct 5, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,284 | $8.12 | $42.9K | Form 4 |
| Oct 5, 2026 | Manuela Valente | Chief People Officer | Sale plan | 4,240 | $8.13 | $34.5K | Form 4 |
| Oct 5, 2026 | Well Daan Van | Chief Legal Officer | Sale plan | 6,168 | $8.12 | $50.1K | Form 4 |
| Sep 21, 2026 | George Cardoza | CFO | Sale plan | 774 | $8.33 | $6.4K | Form 4 |
| Sep 21, 2026 | Ross Muken | CEO | Sale plan | 422 | $8.33 | $3.5K | Form 4 |
| Sep 14, 2026 | Philippe Menu | Chief Medical Officer | Sale | 5,000 | $7.88 | $39.4K | Form 4 |
| Sep 14, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $7.88 | $31.5K | Form 4 |
| Sep 11, 2026 | Well Daan Van | Chief Legal Officer | Sale plan | 6,168 | $7.63 | $47.1K | Form 4 |
| Sep 10, 2026 | Jurgi Camblong | Chair | Sale plan | 8,500 | $7.66 | $65.1K | Form 4 |
| Sep 8, 2026 | Kathy L Hibbs | Director | Sale plan | 6,250 | $8.13 | $50.8K | Form 4 |
| Aug 27, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 10,000 | $8.91 | $89.1K | Form 4 |
| Aug 25, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $8.68 | $43.4K | Form 4 |
| Aug 25, 2026 | Kathy L Hibbs | Director | Sale plan | 6,250 | $8.68 | $54.2K | Form 4 |
| Aug 24, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,000 | $8.80 | $44K | Form 4 |
| Aug 21, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 5,408 | $8.40 | $45.4K | Form 4 |
| Aug 20, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,592 | $8.41 | $38.6K | Form 4 |
| Aug 19, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,000 | $8.20 | $41K | Form 4 |
| Aug 19, 2026 | Manuela Valente | Chief People Officer | Sale plan | 10,000 | $7.94 | $79.4K | Form 4 |
| Aug 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $7.52 | $30.1K | Form 4 |
| Aug 12, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $7.52 | $37.6K | Form 4 |
| Aug 10, 2026 | Jurgi Camblong | Chair | Sale plan | 8,500 | $7.61 | $64.7K | Form 4 |
| Aug 7, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,000 | $7.60 | $38K | Form 4 |
| Aug 7, 2026 | Jurgi Camblong | Chair | Sale plan | 20,000 | $7.23 | $145K | Form 4 |
| Aug 7, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 10,000 | $7.48 | $74.8K | Form 4 |
| Aug 7, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 7,000 | $7.02 | $49.1K | Form 4 |
| Aug 5, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 3,000 | $7.00 | $21K | Form 4 |
| Aug 4, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,000 | $6.95 | $34.8K | Form 4 |
| Aug 4, 2026 | Jurgi Camblong | Chair | Sale plan | 20,000 | $6.92 | $138K | Form 4 |
| Aug 4, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 10,000 | $6.92 | $69.2K | Form 4 |
| Jul 27, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $5.66 | $28.3K | Form 4 |
| Jul 21, 2026 | Jurgi Camblong | Chair | Sale plan | 20,000 | $6.63 | $133K | Form 4 |
| Jul 20, 2026 | Jurgi Camblong | Chair | Sale plan | 19,800 | $6.32 | $125K | Form 4 |
| Jul 20, 2026 | Jurgi Camblong | Chair | Sale plan | 4,581 | $6.17 | $28.3K | Form 4 |
| Jul 13, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $5.70 | $28.5K | Form 4 |
| Jul 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $5.70 | $22.8K | Form 4 |
| Jul 10, 2026 | Jurgi Camblong | Chair | Sale plan | 8,500 | $5.62 | $47.8K | Form 4 |
| Jul 7, 2026 | Jurgi Camblong | Chair | Sale plan | 17,685 | $5.28 | $93.4K | Form 4 |
| Jul 6, 2026 | George Cardoza | CFO | Sale plan | 1,592 | $5.29 | $8.4K | Form 4 |
| Jul 6, 2026 | Manuela Valente | Chief People Officer | Sale plan | 4,241 | $5.05 | $21.4K | Form 4 |
| Jul 6, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 5,285 | $5.10 | $27K | Form 4 |
| Jul 6, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 7,393 | $5.17 | $38.2K | Form 4 |
| Jul 6, 2026 | Ross Muken | CEO | Sale plan | 9,838 | $5.22 | $51.4K | Form 4 |
| Jul 6, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 47 | $5.03 | $236 | Form 4 |
| Jul 6, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 138 | $5.03 | $694 | Form 4 |
| Jul 6, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 31 | $5.09 | $158 | Form 4 |
| Jul 6, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 7,393 | $5.16 | $38.1K | Form 4 |
| Jul 6, 2026 | Jurgi Camblong | Chair | Sale plan | 22,486 | $5.26 | $118K | Form 4 |
| Jun 30, 2026 | Jurgi Camblong | Chair | Sale plan | 200 | $6.30 | $1.3K | Form 4 |
| Jun 30, 2026 | Jurgi Camblong | Chair | Sale plan | 19,650 | $6.02 | $118K | Form 4 |
| Jun 30, 2026 | Jurgi Camblong | Chair | Sale plan | 45,419 | $6.14 | $279K | Form 4 |
| Jun 29, 2026 | Jurgi Camblong | Chair | Sale plan | 350 | $6.00 | $2.1K | Form 4 |
| Jun 29, 2026 | Jurgi Camblong | Chair | Sale plan | 18,060 | $5.87 | $106K | Form 4 |
| Jun 26, 2026 | Jurgi Camblong | CEO | Sale plan | 31,940 | $5.84 | $187K | Form 4 |
| Jun 26, 2026 | Jurgi Camblong | CEO | Sale plan | 18,129 | $5.73 | $104K | Form 4 |
| Jun 25, 2026 | Jurgi Camblong | CEO | Sale plan | 1,373 | $5.70 | $7.8K | Form 4 |
| Jun 25, 2026 | Abhimanyu Verma | Chief Technology Officer | Sale plan | 6,944 | $5.51 | $38.3K | Form 4 |
| Jun 25, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $5.50 | $27.5K | Form 4 |
| Jun 22, 2026 | George Cardoza | CFO | Sale plan | 774 | $5.38 | $4.2K | Form 4 |
| Jun 22, 2026 | Ross Muken | President | Sale plan | 422 | $5.38 | $2.3K | Form 4 |
| Jun 15, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $5.01 | $20K | Form 4 |
| Jun 12, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $4.95 | $24.8K | Form 4 |
| Jun 10, 2026 | Jurgi Camblong | CEO | Sale plan | 8,500 | $5.24 | $44.5K | Form 4 |
| Jun 5, 2026 | George Cardoza | CFO | Purchase | 20,000 | $4.95 | $99K | Form 4 |
| May 26, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $4.95 | $24.8K | Form 4 |
| May 19, 2026 | Ross Muken | President | Sale plan | 761 | $4.60 | $3.5K | Form 4 |
| May 19, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 608 | $4.60 | $2.8K | Form 4 |
| May 19, 2026 | Jurgi Camblong | CEO | Sale plan | 4,486 | $4.60 | $20.6K | Form 4 |
| May 19, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 608 | $4.61 | $2.8K | Form 4 |
| May 19, 2026 | Well Daan Van | Chief Legal Officer | Sale plan | 684 | $4.60 | $3.1K | Form 4 |
| May 19, 2026 | Manuela Valente | Chief People Officer | Sale plan | 380 | $4.60 | $1.7K | Form 4 |
| May 19, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 33 | $4.54 | $150 | Form 4 |
| May 13, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 4,000 | $4.54 | $18.2K | Form 4 |
| May 12, 2026 | Kathy L Hibbs | Director | Sale plan | 7,508 | $4.67 | $35.1K | Form 4 |
| May 12, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $4.67 | $23.4K | Form 4 |
| May 11, 2026 | Jurgi Camblong | CEO | Sale plan | 8,500 | $5.09 | $43.3K | Form 4 |
| Apr 27, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 5,000 | $4.82 | $24.1K | Form 4 |
| Apr 20, 2026 | Manuela Valente | Chief People Officer | Sale plan | 380 | $5.20 | $2K | Form 4 |
| Apr 20, 2026 | Zhenyu Xu | Chief Scientific Officer | Sale plan | 608 | $5.21 | $3.2K | Form 4 |
| Apr 20, 2026 | Well Daan Van | Chief Legal Officer | Sale plan | 684 | $5.20 | $3.6K | Form 4 |
| Apr 20, 2026 | Jurgi Camblong | CEO | Sale plan | 4,486 | $5.21 | $23.4K | Form 4 |
| Apr 20, 2026 | Philippe Menu | Chief Medical Officer | Sale plan | 608 | $5.20 | $3.2K | Form 4 |
| Apr 20, 2026 | Ross Muken | President | Sale plan | 760 | $5.20 | $4K | Form 4 |
| Apr 20, 2026 | Kevin Puylaert | Chief Sales Officer | Sale | 33 | $5.08 | $168 | Form 4 |
Latest 100 of 149 trades in the last 12 months.
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Jurgi Camblong | Chief Executive Officer, Director | – | $2.8M | Nov 10, 2026 |
| Zhenyu Xu | Chief Scientific Officer | – | $728K | Nov 13, 2026 |
| Philippe Menu | Chief Medical Officer | – | $548K | Nov 12, 2026 |
| Ross Muken | President | $137K | $240K | Nov 6, 2026 |
| George Cardoza | Chief Financial Officer | $240K | $66.4K | Nov 6, 2026 |
| Abhimanyu Verma | Chief Technology Officer | – | $283K | Oct 5, 2026 |
| Kathy L Hibbs | Director | – | $189K | Nov 10, 2026 |
| Manuela Valente | Chief People Officer | – | $184K | Oct 5, 2026 |
| Well Daan Van | Chief Legal Officer | – | $165K | Nov 9, 2026 |
| Kevin Puylaert | Chief Sales Officer | – | $6.3K | Oct 5, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
SOPH short interest
1.15M SOPH shares are sold short. Over the last 12 reports the number of shares short went up 389%.
As of Oct 30, 2026, 1.15M SOPH shares were sold short, up 14.8% from the report before. At the average daily volume of 438,231 shares, buying them all back would take about 2.6 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 1.15M | – | +15% | 438,231 | 2.6 |
| Oct 15, 2026 | 1.00M | – | -11% | 691,908 | 1.4 |
| Sep 30, 2026 | 1.12M | – | +5% | 653,869 | 1.7 |
| Sep 15, 2026 | 1.07M | – | -3% | 638,880 | 1.7 |
| Aug 31, 2026 | 1.10M | – | +19% | 575,500 | 1.9 |
| Aug 14, 2026 | 930,712 | – | +21% | 557,829 | 1.7 |
| Jul 31, 2026 | 768,289 | – | +16% | 290,198 | 2.6 |
| Jul 15, 2026 | 661,352 | 0.97% | +4% | 313,792 | 2.1 |
| Jun 30, 2026 | 636,132 | 0.93% | +141% | 459,329 | 1.4 |
| Jun 15, 2026 | 263,601 | 0.38% | -6% | 140,941 | 1.9 |
| May 29, 2026 | 279,103 | 0.41% | +19% | 64,910 | 4.3 |
| May 15, 2026 | 234,741 | 0.34% | +18% | 119,046 | 2.0 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Famous investors that hold SOPH
6 of the 50 well-known investors we track reported holding SOPH in their latest 13F filing. The largest position is Chuck Akre's, worth $31.2M.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Chuck Akre · Akre Capital Management | Q3 2026 | 3.72M | $31.2M | 0.7% | No change |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 1.57M | $13.1M | 0.0% | New |
| Ken Griffin · Citadel Advisors | Q3 2026 | 746,052 | $6.3M | 0.0% | +1838% |
| Jim Simons · Renaissance Technologies | Q3 2026 | 270,900 | $2.3M | 0.0% | +139% |
| Israel Englander · Millennium Management | Q3 2026 | 214,308 | $1.8M | 0.0% | +55% |
| Paul Tudor Jones · Tudor Investment Corp | Q3 2026 | 152,886 | $1.3M | 0.0% | New |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named SOPH in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 12, 2026 | Schindel Yair Chaim | 13D/A | 6.2% |
| Nov 12, 2026 | Schindel Yair Chaim | 13D/A | 6.2% |
Questions about SOPHiA GENETICS SA (SOPH) stock
Who owns the most SOPH stock?
The largest reported owner of SOPHiA GENETICS SA (SOPH) is Generation Investment Management LLP, with 9.9% of the company. In total, 72 funds and institutions reported holding SOPH at the end of Q2 2026, together about 54% of the shares. See the largest owners.
Are SOPH insiders buying or selling?
In the last 12 months, SOPH insiders reported 3 open-market purchases worth $377K and 146 sales worth $5.2M. The latest trade was on Nov 13, 2026. See every trade.
What is the short interest in SOPH?
As of Oct 30, 2026, 1.15M SOPH shares were sold short, up 14.8% from the report before. At the average daily volume of 438,231 shares, buying them all back would take about 2.6 trading days (days to cover). See the history.
Which famous investors hold SOPH?
6 of the 50 well-known investors we track reported SOPH in their latest 13F filing, including Chuck Akre, Steve Cohen, Ken Griffin. The largest position is worth $31.2M. See all holders.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.